Sonoma Pharmaceuticals (NASDAQ:SNOA) Releases Earnings Results, Beats Estimates By $0.21 EPS

Sonoma Pharmaceuticals (NASDAQ:SNOA) posted its earnings results on Thursday. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.21, FiscalAI reports. Sonoma Pharmaceuticals had a negative net margin of 16.26% and a negative return on equity of 43.95%. The firm had revenue of $6.41 million during the quarter, compared to analyst estimates of $4.99 million.

Sonoma Pharmaceuticals Price Performance

Shares of Sonoma Pharmaceuticals stock traded up $0.12 on Thursday, reaching $1.25. The company had a trading volume of 1,508,925 shares, compared to its average volume of 51,039. The firm has a market cap of $5.99 million, a price-to-earnings ratio of -0.66 and a beta of 1.28. The firm’s 50-day moving average price is $1.17 and its two-hundred day moving average price is $1.89. Sonoma Pharmaceuticals has a 1 year low of $0.85 and a 1 year high of $6.92.

Institutional Trading of Sonoma Pharmaceuticals

An institutional investor recently raised its stake in Sonoma Pharmaceuticals stock. DRW Securities LLC boosted its position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 257.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 60,977 shares of the company’s stock after buying an additional 43,907 shares during the quarter. DRW Securities LLC owned 3.59% of Sonoma Pharmaceuticals worth $222,000 as of its most recent filing with the Securities & Exchange Commission. 1.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research report on Friday, July 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Sonoma Pharmaceuticals presently has a consensus rating of “Sell”.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.